Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656961 | 0.87 | POLB (0.61) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL10649973 | 0.80 | POLB (0.50) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL6755136 | 0.78 | SMN1; SMN2 (0.48) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL6755138 | 0.78 | SMN1; SMN2 (0.48) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL6755137 | 0.78 | SMN1; SMN2 (0.48) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL23775752 | 0.78 | SMN1; SMN2 (0.48) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL24125191 | 0.75 | CREBBP (0.57) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL2745305 | 0.75 | CREBBP (0.57) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL3618121 | 0.73 | POLB (0.47) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL14250616 | 0.72 | SMN1; SMN2 (0.43) | POLBSMN1; SMN2HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107372-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | LANTER JAMES C (US) | 2005-05-19 | — | — | US | disclosed |
| US-6858621-B2 | 2-(quinolonyl)-fused heterocycles as androgen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1501835-A2 | 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040014743-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003090672-A2 | 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014743-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | AR, NR5A1, ESRRA | POLB 2475/4885SMN1; SMN2 4533/4885HDAC1 266/4885 |
| US-20050107372-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | AR, NR5A1, CYP19A1 | POLB 2417/4885SMN1; SMN2 4570/4885HDAC1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.